Harrow (Harrow) GF Value : $17.63 (As of May. 01, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Harrow GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-01), Harrow's share price is $10.19. Harrow's GF Value is $17.63. Therefore, Harrow's Price-to-GF-Value for today is 0.58.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Harrow is Possible Value Trap, Think Twice.

Harrow (NAS:HROW) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Harrow's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	10.19	/	17.63
	=	0.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harrow GF Value Related Terms

Thank you for viewing the detailed overview of Harrow's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Harrow (Harrow) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harrow Inc (NAS:HROW) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

102 Woodmont Boulevard, Suite 610, Nashville, TN, USA, 37205

Website

https://www.harrow.com

Harrow Inc is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the U.S. market. Harrow helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans each year.

Executives

Mark L Baum	director, 10 percent owner, officer: Chief Executive Officer	C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130
Opaleye Management Inc.	10 percent owner	ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Martin A. Makary	director	102 WOODMONT BLVD., SUITE 610, NASHVILLE TN 37205
Van Horn R. Lawrence	director	354 COOL SPRINGS BLVD., SUITE 106, FRANKLIN TN 37067
Andrew Boll	officer: VP, Accounting and Reporting	437 S HWY 101, STE 209, SOLANA BEACH CA 92075
Lindstrom Richard L Md	director	2811 WESTWOOD PL, WAYZATA MN 55391
Perry J. Sternberg	director	102 WOODMONT BLVD., SUITE 610, NASHVILLE TN 37205
Teresa Sparks	director	40 BURTON HILLS BOULEVARD SUITE 500, NASHVILLE TN 37215
Robert J Kammer	director, 10 percent owner, officer: Chairman of the Board	1440 28TH STREET, SUITE 9, BOULDER CO 80303
Longboard Capital Advisors, Llc	other: Institutional Investor	9665 WILSHIRE BLVD., SUITE 430, BEVERLY HILLS CA 90212
Brett Conrad	other: Managing Mbr of Longboard Cap.	1312 CEDAR ST., SANTA MONICA CA 90405
Clayton D Edwards	officer: Chief Operating Officer	12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130
Anthony Principi	director	2300 WEST PLANO PARKWAY, M/S D2420, PLANO TX 75244
Donald Paul Miloni	10 percent owner	1425 GREENWOOD LANE, GREENWOOD VILLAGE CO 80125
John P. Saharek	officer: Chief Commercial Officer	12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130